SVILE versus GELOX on the treatment of patients with extranodal NK/T cell lymphoma, nasal type: a perspective clinical study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPC-14005745

Enrollment

Unknown

Registered

2014-12-31

Start date

2015-01-01

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal Nature/Killer-T Cell Lymphoma, Nasal Type

Interventions

treatment group:SVILE regimen chemotherpy 3 cycles

control group:GELOX regimen chemotherapy 3 cycles

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. newly diagnosed extranodal NK/T cell lymphoma, nasal type; 2. age ranges from 18 to 70 years; 3. the estimated survival period exceeds 3 months.

Exclusion criteria

Exclusion criteria: 1. stage I patients without any high-risk factors; 2. companied with severe cardiopulmonary disease or kidney and liver dysfunction; 3. patients who can not tolerate chemotherapy; 4. pregnant women.

Design outcomes

Primary

Measure	Time frame
Overall response rate;	—

Secondary

Measure	Time frame
complete remission rate;overall survival (OS);progression-free survival(PFS);	—

Countries

China

Contacts

Public ContactWang Jingwen

trwangjw@163.com+86-010-58268471

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026